Abiopharma

FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic Syndromes

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

New Form 6-K - Quantum Biopharma Ltd. Filed: 2025-08-07 AccNo: 0001171843-25-005150 Size: 30 KB

New Form 6-K - XORTX Therapeutics Inc. Filed: 2025-08-07 AccNo: 0001171843-25-005151 Size: 17 KB

New Form 6-K - ProQR Therapeutics N.V. Filed: 2025-08-07 AccNo: 0001558370-25-010635 Size: 3 MB

Natera - Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Insulet - Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency1)

Immunocore reports second quarter financial results and provides a business update

Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

LENSAR Reports Second Quarter 2025 Results and Provides Business Update